Literature DB >> 7979588

Combination therapy with methotrexate and sulphasalazine in rheumatoid arthritis--tolerance of therapy.

R S Axtens, E F Morand, G O Littlejohn.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7979588      PMCID： PMC1005442          DOI： 10.1136/ard.53.10.703-a

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  10 in total

1.  Drug interactions with methotrexate.

Authors:  B J Liddle; J R Marsden
Journal:  Br J Dermatol       Date:  1989-04       Impact factor: 9.302

Review 2.  The use of combinations of disease-modifying antirheumatic agents in rheumatoid arthritis.

Authors:  H E Paulus
Journal:  Arthritis Rheum       Date:  1990-01

3.  Severe bone marrow failure due to low dose oral methotrexate.

Authors:  R Buchbinder; S Hall; P F Ryan; G O Littlejohn; A J Harkness
Journal:  J Rheumatol       Date:  1988-10       Impact factor: 4.666

4.  The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis.

Authors:  S L Morgan; J E Baggott; W H Vaughn; P K Young; J V Austin; C L Krumdieck; G S Alarcón
Journal:  Arthritis Rheum       Date:  1990-01

5.  Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis.

Authors:  G Singh; J F Fries; C A Williams; E Zatarain; P Spitz; D A Bloch
Journal:  J Rheumatol       Date:  1991-02       Impact factor: 4.666

6.  Methotrexate and sulfasalazine combination therapy: is it worth the risk?

Authors:  S L Morgan; J E Baggott; G S Alarcón
Journal:  Arthritis Rheum       Date:  1993-02

7.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.

Authors:  F C Arnett; S M Edworthy; D A Bloch; D J McShane; J F Fries; N S Cooper; L A Healey; S R Kaplan; M H Liang; H S Luthra
Journal:  Arthritis Rheum       Date:  1988-03

8.  Life table analysis of 879 treatment episodes with slow acting antirheumatic drugs in community rheumatology practice.

Authors:  E F Morand; P I McCloud; G O Littlejohn
Journal:  J Rheumatol       Date:  1992-05       Impact factor: 4.666

9.  Antifolate actions of sulfasalazine on intact lymphocytes.

Authors:  C L Baum; J Selhub; I H Rosenberg
Journal:  J Lab Clin Med       Date:  1981-06

10.  Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts.

Authors:  F Wolfe; D J Hawley; M A Cathey
Journal:  J Rheumatol       Date:  1990-08       Impact factor: 4.666
  10 in total
  1 in total

Review 1.  Sulfasalazine. A review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis.

Authors:  C P Rains; S Noble; D Faulds
Journal:  Drugs       Date:  1995-07       Impact factor: 9.546
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.